78 results about "Inositol monophosphate" patented technology

The present invention relates to a composition for gelatin coating and a gelatin coating characterized by containing a gelatin (A) and an inositol phosphate (B) represented by a general formula: C₆H_12-n.(H₂PO₄)_n (in the formula, n represents an integer from 1 to 6), and a preparation using the same.

The invention provides compounds of formula (I) in which R1, R2, R3, R4 and R5 are independently selected from hydrogen and chromogenic substituents, and X is selected from the group consisting of hydroxyl; OR6 wherein R6 is selected from the group consisting of C1-C4 alkyl; and O-Me+ wherein Me+ is a cation derived from an organic or inorganic base. A preferred species of formula (I) is 4-Methylumbelliferyl myo-inositol-1-phosphate and salts thereof with an organic or inorganic base. The invention also provides fluorogenic methods for detecting various pathogenic bacteria, e.g., Listeria, Staphylococcus and Clostridium species, using substrates containing at least one formula (I) compound. A kit for detecting a phosphatidyl-inositol-specific phospholipase C enzyme as an indication of bacterial activity is disclosed.

The invention relates to a method for preparing inositol through enzymic catalysis. The method comprises the following steps: performing enzyme-catalyzed conversion on a polysaccharide or an oligosaccharide which takes glucose as a unit to obtain glucose-1-phosphate; performing enzyme-catalyzed conversion on the glucose-1-phosphate to obtain glucose-6-phosphate; performing enzyme-catalyzed conversion on the glucose-6-phosphate to obtain inositol-1-phosphate; performing enzyme-catalyzed conversion on the inositol-1-phosphate to obtain inositol. The invention also provides an inositol product which is prepared according to the method. According to the method, the conversion efficiency of the inositol is effectively improved; moreover, a production process is simple, pollution-free, and low in production cost.

The invention relates to inhibitors of PI5P4K inhibitors useful in the treatment of cancers, neurodegenerative diseases, inflammatory disorders, and metabolic diseases, having the Formula:

where A1, A2, G, R1, R2, R3, R4, and W are described herein.

The invention relates to inhibitors of PI5P4K inhibitors useful in the treatment of cancers, neurodegenerative diseases, inflammatory disorders, and metabolic diseases, having the Formula:

where A1, A2, G, R₁, R₂, R₃, R₄, and W are described herein.

The invention relates to inhibitors of PI5P4K inhibitors useful in the treatment of cancers, neurodegenerative diseases, inflammatory disorders, and metabolic diseases, having the Formula:

where A, B, R₁, X₁, X₂, and W are described herein.

The invention relates to the field of bioengineering, in particular to an inositol-3-phosphate synthase mutant and application of the inositol-3-phosphate synthase mutant in construction of corynebacterium glutamicum for high yield of glutamine. It is found that after 84th-site serine of inositol-3-phosphate synthase is mutated into other amino acids, the glutamine production capacity of corynebacterium glutamicum can be enhanced in corynebacterium glutamicum. Compared with a wild strain without mutation, the corynebacterium glutamicum has the advantages that the glutamine production capacity of the corynebacterium glutamicum is enhanced, the glutamine yield is increased to 30.7 g/L from 28.5 g/L, the acid production is increased by 7.7%, and screening and construction of a glutamine high-yield strain are facilitated.

The invention relates to inhibitors of PI5P4K inhibitors useful in the treatment of cancers, neurodegenerative diseases, inflammatory disorders, and metabolic diseases, having the Formula:

The present disclosure relates to a method for preparing myo-inositol using myo-inositol monophosphate synthase consisting of an amino acid sequence of SEQ ID NO: 1 and/or myo-inositol monophosphate phosphatase consisting of an amino acid sequence of SEQ ID NO: 3.

The invention discloses a preparation method of high-purity sugammadex sodium. The high-purity sugammadex sodium is prepared from inositol phosphate and derivatives thereof. The specific process comprises the following steps of adding a specific type of protective agent into a crude sugammadex sodium product, and performing recrystallizing under the protection of inert gas to obtain a pure sugammadex sodium product, wherein the protective agent is selected from the inositol phosphate and the derivatives thereof, such as inositol hexaphosphate and salts or esters thereof, partial degradation products of the inositol hexaphosphate, such as inositol pentaphosphate, inositol tetraphosphate, inositol triphosphate, inositol diphosphate and inositol monophosphate, and one or a mixture of two or more of the above-mentioned substances and salts or esters thereof in any proportion. The method is simple and convenient to operate, high in product purity, good in safety, few in anaphylactic reaction, good in economical efficiency and more suitable for industrial production.

The invention relates to the field of enzymatic catalytic preparation of inositol, in particular to an enzymatic preparation method for producing inositol by complete phosphorolysis of cellulose. According to the preparation method of inositol, pretreated cellulose (the main component is fiber polysaccharide) is used as a substrate for the enzyme catalytic reaction; and cellulose polysaccharide phosphorylase, cellobiose phosphorylase, polyphosphate glucokinase, phosphoglucomutase, inositol-1-phosphate synthase and inositol monophosphatase are adopted to catalyze complete phosphorolysis of cellulose polysaccharide into inositol. By optimizing the multienzyme reaction process and controlling the reaction temperature in stages, the conversion efficiency of the substrate and the inositol yieldare significantly improved, and the reaction time is shortened. The technical method realizes the complete phosphorolysis of the cellulose substrate, and can also be used for other in-vitro multi-enzyme reaction systems to catalyze cellulose polysaccharide for production of hydrogen, electricity or other bio-based chemicals.

The invention discloses application of effective inhibitor of III-type phosphatidylinositol phosphate kinase in preparing drug for treating or preventing influenza virus infection. Research results prove that the effective inhibitor, namely a small molecule compound: 6-amino-N-[3-[4-(4-morpholinyl)pyridine[3', 2':4, 5] furan [3, 2-d] pyrimidine-2-base] phenyl]3-pyridine carboxamide can inhibit copying of influenza A virus subtype H1N1 amantadine drug-tolerant strain, influenza A virus subtype H6N6 strain, influenza A virus subtype H7N8 strain and influenza B virus in a dosage-dependent mannerwithin a nontoxic range, thereby having great wide-spectrum influenza virus resistant activity. Therefore, the small molecular compound is safe, efficient and little in toxic and side effect during clinical treatment of influenza.

The invention relates to a dunaliellaviridis myo-Inositol-1-phosphatesynthase gene (DvMIPS), and a protein coded thereby and application thereof. The gene is a DNA (Deoxyribonucleic Acid) sequence shown as SEQ ID NO1. According to the invention, the myo-Inositol-1-phosphatesynthase gene DvMIPS is separated from dunaliellaviridis for the first time; and conversion of yeast cells shows that the gene not only has the phosphatesynthase function, but also has the application value of improving the biological salt tolerance character.

Herein is disclosed a method of generating ascorbic acid from yeast transformed with a mannose epimerase. In a further embodiment, the yeast can be further transformed with a myoinositol phosphatase. In the method, the transformed yeast can produce L-ascorbic acid from D-glucose. The transformed yeast has been observed to have increased growth rate, cell density, or survival when cultured on appropriate media.

The invention relates to a kit for diagnosing/measuring lithium by utilizing the technologies of the enzymic colorimetry and the enzyme linked immunosorbent assay, wherein, the activity of the kit can be inhibited by lithium. The invention further relates to a method, a principle and the composition and the components of a reagent for measuring the concentration of lithium, and belongs to the technical field of medical/industrial/environmental inspection and measurement. The main components of the kit include a buffer solution, coenzyme, magnesium chloride, inositol-1-phosphate, sucrose, inositol-1-phosphatase, sucrose phosphorylase, fructose dehydrogenase and a stabilizer. Through mixing a check sample and a lithium sample respectively with the reagent by a certain volume ratio, a series of enzymatic reactions occur, then the reactant is placed under an ultraviolet/visible light analyzer, the degree/velocity of the increase in absorbance at 340 nm of the dominant wavelength is detected, and the difference in the degree/velocity of the increase between the check sample and lithium sample is compared, thereby measuring the concentration of lithium.

The invention discloses a protein delayed expression switch. By combined use of a growth phase promoter PrpsL and a degradation tag SsrA of a C terminal, expression of target protein can be automatically controlled to be switched on at the late stage of cell culture without artificial control and addition of an inducer. By introducing genetic engineering bacteria used for producing glucaric acid and constructed by the protein delayed expression switch, inositol-1-phosphate synthase (INO1) of the target protein can be controlled; expression is switched on only after cell density reaches a certain degree; the protein delayed expression switch has important value in synthesis efficiency of the glucaric acid; and a new method and thought are also provided in the aspect of producing the glucaric acid by microorganism fermentation.